Protagonist Therapeutics, Inc.
PTGX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $4,712 | $5,546 | $28,321 | $170,638 |
| % Growth | -15% | -80.4% | -83.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $4,712 | $5,546 | $28,321 | $170,638 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $40,003 | $37,036 | $35,893 | $34,904 |
| G&A Expenses | $11,130 | $10,551 | $11,738 | $8,954 |
| SG&A Expenses | $11,130 | $10,551 | $11,738 | $8,954 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $51,133 | $47,587 | $47,631 | $43,858 |
| Operating Income | -$46,421 | -$42,041 | -$19,310 | $126,780 |
| % Margin | -985.2% | -758% | -68.2% | 74.3% |
| Other Income/Exp. Net | $7,082 | $7,442 | $7,655 | $6,884 |
| Pre-Tax Income | -$39,339 | -$34,599 | -$11,655 | $133,664 |
| Tax Expense | $0 | $172 | $0 | $1,990 |
| Net Income | -$39,339 | -$34,771 | -$11,655 | $131,674 |
| % Margin | -834.9% | -627% | -41.2% | 77.2% |
| EPS | -0.62 | -0.55 | -0.19 | 2.11 |
| % Growth | -12.7% | -189.5% | -109% | – |
| EPS Diluted | -0.62 | -0.55 | -0.19 | 1.98 |
| Weighted Avg Shares Out | 63,772 | 63,511 | 62,964 | 62,328 |
| Weighted Avg Shares Out Dil | 63,772 | 63,511 | 62,964 | 66,407 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7,049 | $7,406 | $7,573 | $6,853 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $361 | $304 | $239 | $536 |
| EBITDA | -$38,978 | -$41,737 | -$19,071 | $127,316 |
| % Margin | -827.2% | -752.6% | -67.3% | 74.6% |